Annual Meeting Main Page | Annual Meeting Highlights | Program Purpose | Presentation Slides & Schedule
Faculty | Abstracts | Hot Topic Symposium | Hot Topic Highlights | Award Recipients
Early Career Scientists | Session Goals | Final Program | Photos | Meeting Summary
October 2 - 4, 2010 
Hyatt Regency Washington on Capitol Hill
Washington, D.C.
Program Schedule
Friday, October 1 |
|
| 8:00 am - 5:00 pm | Workshop on Monoclonal Antibodies in Cancer For more information, click here. |
| 8:00 am - 5:00 pm | Primer on Tumor Immunology and Biological Therapy of Cancer For more information, please click here. |
Saturday, October 2 |
|
| 7:50 am - 8:00 am | President's Welcome Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
| 8:00 am - 8:45 am | Richard V. Smalley, MD Memorial Lectureship Immune Checkpoint Blockade in Cancer Therapy: New Insights and OpportunitiesJames P. Allison, PhD - Memorial Sloan-Kettering Cancer Center |
| 8:45 am - 11:30 am 8:45 am - 9:15 am 9:15 am - 9:45 am 9:45 am - 10:00 am 10:30 am - 10:45 am 10:45 am - 11:00 am 11:00 am - 11:30 am |
Plenary Session: Dendritic Cells and Cancer Co-Chairs: Carl G. Figdor, PhD - Nijmegen Centre for Molecular Life Sciences Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute Dendritic Cell Vaccination in Cancer: Achievements, Obstacles and Future Perspectives Carl G. Figdor, PhD - Nijmegen Centre for Molecular Life Sciences Progress in the Active Immunotherapy of Prostate Cancer: Sipuleucel-T, an Autologous Cellular Immunotherapy David L. Urdal, PhD - Dendreon Corporation Therapeutic Vaccination with Autologous mRNA Electroporated Dendritic Cells in Patientswith Advanced Melanoma Bart Neyns, MD, PhD - Universitair Ziekenhuis Brussel Resistance to the Proapoptotic Effects of IFN-γ on Melanoma Cells Used in Patient-SpecificDendritic Cell Immunotherapy is Associated with Improved Overall Survival Andrew N. Cornforth, PhD - Hoag Memorial Hospital Cancer Center IFN-gamma is Central to Both Immunogenic and Tolerogenic Properties of Dendritic CellsAfter IL-12 and GM-CSF Microsphere Treatment Jamie L. Harden - State University of New York, University at Buffalo Polarized Dendritic Cells in the Immunotherapy of Established Cancer: Roles of Signal 3 and Signal 4 Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute |
| 1:30 pm - 3:00 pm 1:30 pm - 2:00 pm 2:00 pm - 2:30 pm 2:30 pm - 2:45 pm 2:45 pm - 3:00 pm |
Concurrent Session I: Targeted Therapeutics and Immunotherapy Co-Chairs: Mary L. Disis, MD - University of Washington Keiran S. Smalley, PhD - H. Lee Moffitt Cancer & Research Institute Immune Modulation of Breast Cancer Mary L. Disis, MD - University of Washington Overcoming BRAF Inhibitor Resistance in Melanoma Keiran S. Smalley, PhD - H. Lee Moffitt Cancer & Research Institute The High-Dose Aldesleukin (IL-2) "Select" Trail in Patients with Metastatic Renal CellCarcinoma Kim A. Margolin, MD - Seattle Cancer Care Alliance In Vivo Modeling and Detection of Ovarian Cancer Vascular Marker TEM1 Chunsheng Li, PhD - Ovarian Cancer Research Center, University of Pennsylvania |
| 1:30 pm - 3:00 pm 1:30 pm - 2:00 pm 2:00 pm - 2:15 pm 2:15 pm - 2:30 pm 2:30 pm - 3:00 pm |
Concurrent Session II: Innate / Adaptive Immune Interplay in Cancer Co-Chairs: Vincenzo Cerundolo, MD, PhD - University of Oxford - Institute of Molecular Medicine Laurence Zitvogel, MD, PhD - Institute Gustave Roussy The Role of Invariant NKT Cells at the Interface of Innate and Adaptive ImmunityVincenzo Cerundolo, MD, PhD - University of Oxford - Institute of Molecular Medicine T-Regulatory Cells in Colon Cancer: Friend or Foe?Khashayarsha Khazaie, PhD, DSc - Northwestern University, Robert Lurie Comprehensive Cancer Ctr. Myeloid-Derived Suppressor Cells and Decreased Interferon Responsiveness in Tumor-Bearing Mice Bethany Mundy - The Ohio State University The Desirable Cell Death for Chemotherapy of Cancer Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
| 3:15 pm - 5:15 pm 3:15 pm - 3:35 pm 3:35 pm - 3:55 pm 3:55 pm - 4:15 pm 4:15 pm - 4:35 pm 4:35 pm - 5:15 pm |
Plenary Session: Clinical Trial Endpoints Co-Chairs: F. Stephen Hodi, MD - Dana-Farber Cancer Institute Vernon K. Sondak, MD - H. Lee Moffitt Cancer Decoding the Tower of BabelVernon K. Sondak, MD - H. Lee Moffitt Cancer & Research Center Immune-Related Response Criteria - Finding Missed Signals of Activity for Immunotherapy F. Stephen Hodi, MD - Dana-Farber Cancer Institute Defining Response in Prostate Cancer ImmunotherapyLawrence Fong, MD - University of California - San Francisco Moving Beyond Tumor Size: A New Paradigm in Cancer Imaging Annick Van den Abbeele, MD - Dana-Farber Cancer Institute Panel Discussion |
| 5:15 pm - 5:45 pm | Clinical Immunotherapy Guidelines: A New iSBTc Initiative Howard L. Kaufman, MD - Rush University Medical Center |
| 5:45 pm - 6:15 pm | iSBTc Membership Business Meeting |
Sunday, October 3 |
|
| 8:00 am - 8:45 am | Keynote Address Therapeutic vaccination against HPV16-induced disease Cornelius J.M. Melief, MD, PhD - Leiden University Medical Center |
| 8:45 am - 11:30 am 8:45 am - 9:15 am 9:15 am - 9:45 am 9:45 am - 10:00 am 10:30 am - 11:00 am 11:00 am - 11:15 am 11:15 am - 11:30 am |
Plenary Session: Vaccine Combinations Co-Chairs: Pierre Coulie, MD, PhD - de Duve Institute and University of Louvain Victor H. Engelhard, PhD - University of Virginia School of Medicine Numbers and Functions of Lymphocytes in Human Melanoma Metastases Pierre Coulie, MD, PhD - de Duve Institute and University of Louvain Phosphopeptides Presented by MHC Class I and Class II Molecules: A New Category of Tumor Associated Antigens with Immunotherapeutic Potential Victor H. Engelhard, PhD - University of Virginia School of Medicine Induction of CD8+ T Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations with α-Type-1-Polarized Dendritic Cells and Poly-ICLC in Patients with Recurrent Malignant GliomaHideho Okada, MD, PhD - University of Pittsburgh Cancer Institute Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint BlockadeJedd D. Wolchok, MD, PhD - Memorial Sloan-Kettering Cancer Center T Cell Activation, PSMA Seroconversion and Increased Th17 Rates are Associated with Favorable Clinical Outcome in Prostate Cancer Patients Treated with Prostate GVAX and Anti-CTLA-4 Immunotherapy Saskia J. Santegoets, PhD - VU University Medical Center Vaccine Sites as Sinks and Graveyards for Tumor-specific T CellsWillem W. Overwijk, PhD - University of Texas, MD Anderson Cancer Center |
| 11:30 am - 11:45 am | Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, MD - University of California, Los Angeles |
| 1:30 pm - 2:50 pm 1:30 pm - 1:50 pm 1:50 pm - 2:10 pm 2:10 pm - 2:30 pm 2:30pm - 2:50 PM |
Presidential Abstract Session Chair: Bernard A. Fox, PhD - Earle A. Chiles Research Institute Interferon-β Secretion in the Tumor Microenvironment can Cause Potent Tumor Control Through Host Cells Independently from Adaptive Immunity Robbert Spaapen, PhD - University of Chicago 4-1BB Activation Induces the Master-Regulator EOMES and a Broad-Spectrum TH1 Phenotype which Synergizes with CTLA-4 Blockade to Reject B16 Melanoma Michael A. Curran, PhD - Memorial Sloan-Kettering Cancer Center Ovarian Cancer Cells Ubiquitously Express HER-2 and can be Distinguished from Normal Ovary by Genetically Redirected T Cells Evripidis Lanitis, BS - University of Pennsylvania Large-Scale Profiling of Circulating Serum Markers, Single Cell Polyfunctionality and Antigen Diversity of T Cell Response Against Melanoma Chao Ma, MS - California Institute of Technology |
| 3:15 pm - 4:45 pm 3:15 pm - 3:45 pm 3:45 pm - 4:00 pm 4:00 pm - 4:15 pm 4:15 pm - 4:45 pm |
Concurrent Session I: Countering Negative Regulation Co-Chairs: Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research Weiping Zou, MD, PhD - University of Michigan Is it Possible to Correct the Impaired Function of Human Tumor-Infiltrating T Lymphocytes? Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research The Multikinase Inhibitor Sorafenib Reverses the Suppression of IL-12 and Enhancement of IL-10 by PGE2 in Murine MacrophagesLeisha A. Emens, MD, PhD - Johns Hopkins University School of Medicine Loss of HLA-DR Expression on CD14+ Cells: A Common Marker of Immunosuppression in Cancer PatientsMichael P. Gustafson, PhD - Mayo Clinic Inflammatory Tregs in the Human Tumor and Chronic Inflammatory Microenvironments Weiping Zou, MD, PhD - University of Michigan |
| 3:15 pm - 4:45 pm 3:15 pm - 3:45 pm 3:45 pm - 4:00 pm 4:00 pm - 4:30 pm 4:30 pm - 4:45 pm |
Concurrent Session II: Immune Cell Trafficking to Tumor Microenvironment Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago Elizabeth M. Jaffee, MD - Johns Hopkins University Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironmentThomas F. Gajewski, MD, PhD - University of Chicago Spatial and Temporal Regulation of CXCR3 Chemokine Production and CD8 T Cell Infiltration in the Metastatic Melanoma Microenvironment David W. Mullins, PhD - University of Virginia Effector/Memory Regulatory T Cells and Their Role in the Tumor Microenvironment Elizabeth M. Jaffee, MD - Johns Hopkins University NGR-TNF, A Selective Vessel-Targeting Agent, Increases the Therapeutic Potential of Chemo-Immunotherapy Arianna Calcinotto - San Raffaele Scientific Institute |
| 5:00 pm - 5:30 pm | Update: 2009 iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer Lisa H. Butterfield, PhD - University of Pittsburgh |
| 5:30 pm - 6:00 pm | Cancer Immunotherapy Trials Network Update William Merritt PhD - National Cancer Institute Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center |
Monday, October 4 |
|
| 8:00 am - 10:15 am 8:00 am - 8:30 am 8:30 am - 8:45 am 8:45 am - 9:00 am 9:00 am - 9:30 am 9:30 am - 9:45 am 9:45 am - 10:15 am |
Plenary Session: Adoptive T Cell Transfer: The Next Wave Co-Chairs: Patrick Hwu, MD - University of Texas, MD Anderson Cancer Center Ton N. Schumacher, PhD - Netherlands Cancer Institute Improving the Efficacy and Safety of G-M Virus-Specific T cells for Solid TumorsMalcolm K. Brenner, MD, PhD - Baylor College of Medicine Functional Reprogramming of the Tumor Stroma by IL-12 Engineered T Cells is Required for Anti-Tumor ImmunitySid Kerkar, MD - National Cancer institute, Center for Cancer Research, NIH Noninvasive Positron Emission Tomography (PET) Imaging of Sleeping Beauty (SB) Modified CD19-Specific T Cells Expressing Herpes Simplex Virus1-Thymidine KinasePallavi Raja Manuri, PhD - University of Texas, MD Anderson Cancer Center Dissection of Therapy-Induced Melanoma-Reactive Cytotoxic T Cell ResponsesTon N. Schumacher, PhD - Netherlands Cancer Institute Therapeutic Cell Engineering Using Surface-Conjugated Synthetic NanoparticlesMatthias Stephen, MD, PhD - Massachusetts Institute of Technology Adoptive T Cell Therapy for Metastatic Melanoma: The MD Anderson Experience Laszlo G. Radvanyi, PhD - University of Texas, MD Anderson Cancer Center Patrick Hwu, MD - University of Texas, MD Anderson Cancer Center |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
